US · Healthcare · Biotechnology
EPS came in at -0.81 against a street estimate of -0.71 — a miss of 14.1%.
Analysts rate Cullinan Oncology LLC a strong buy (12 buy, 0 hold, 0 sell out of 12) with an average price target of $33.45.
| Fund | Stake |
|---|---|
| MPM Oncology Impact Management LP | 15.12% |
| Lynx1 Capital Management, LP | 13.93% |
| Bvf Inc | 8.94% |
| BlackRock Inc | 8.13% |
| T. Rowe Price Associates, Inc. | 5.95% |
| State Street Corp | 5.70% |
| Kynam Capital Management, LP | 4.84% |
| Vanguard Capital Management, LLC | 4.06% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q4 2026 HEADLINE NUMBERS • Cullinan Therapeutics initiated a U.S. FDA New Drug Application (NDA) submission for zipalertinib plus platinum-based chemotherapy | 2026-10-02 |
| Reg FD disclosure · Q3 2026 CULLINAN THERAPEUTICS, INC. — 8-K SUMMARY HEADLINE NUMBERS • No financial results reported in this filing — this is a milestone/pipeline update anno | 2026-09-24 |
| Reg FD disclosure · Q3 2026 CULLINAN THERAPEUTICS, INC. – 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Company announced Phase 3 REZILIENT3 clinical trial results for zipalertin | 2026-09-14 |
| Reg FD disclosure · Q3 2026 CULLINAN THERAPEUTICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Company: Cullinan Therapeutics, Inc. (ticker: CGEM, Nasdaq) • Announcement date: August | 2026-08-13 |
| Quarterly report · Q2 2026 CULLINAN THERAPEUTICS, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash & Investments Position (June 30, 2026): $78.6 million cash + $255.9 milli | 2026-08-06 |
| Results announced · Q3 2026 CULLINAN THERAPEUTICS INC. — Q2 2026 FINANCIAL & BUSINESS SUMMARY HEADLINE NUMBERS • Cash and investments: $356.0 million as of June 30, 2026 • Proj | 2026-08-06 |
| Shareholder vote results · Q2 2026 CULLINAN THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual Stockholder Meeting held June 16, 2026 • Company trades on Nasdaq Global Select | 2026-06-16 |
| Reg FD disclosure · Q2 2026 CULLINAN THERAPEUTICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Company ticker: CGEM (Nasdaq Global Select Market) • Delaware incorporation, IRS ID 81- | 2026-06-10 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cullinan Oncology LLC — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.